BAVA — Bavarian Nordic A/S Share Price
- DKK11.76bn
- DKK10.04bn
- DKK7.06bn
- 30
- 66
- 68
- 55
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 11.56 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -42.99% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.14 | ||
Price to Tang. Book | 3.05 | ||
Price to Free Cashflow | 82.95 | ||
Price to Sales | 1.67 | ||
EV to EBITDA | 4.88 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.99% | ||
Return on Equity | 16.87% | ||
Operating Margin | 21.28% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | DKKm | 662.49 | 1,852.38 | 1,897.88 | 3,150.79 | 7,062.34 | 5,241.71 | 5,683.37 | 69.78% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -56.82 | +37.37 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Directors
- Gerard van Odijk CHM (64)
- Paul Chaplin PRE (54)
- Anders Pedersen VCH (70)
- Henrik Juuel CFO (56)
- Henrik Birk COO (48)
- Laurence De Moerlooze EVP (57)
- Jean-Christophe May EVP (54)
- Anu Kerns EVP (49)
- Anne Eberhard IND (58)
- Erik Hansen IND (69)
- Peter Kurstein-Jensen IND (65)
- Elizabeth McKee Anderson IND (64)
- Frank Verwiel IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 1st, 1992
- Public Since
- November 2nd, 1998
- No. of Shareholders
- 123,000
- No. of Employees
- 1,379
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 78,053,880
- Address
- Philip Heymans Alle 3, HELLERUP, 2900
- Web
- https://www.bavarian-nordic.com/
- Phone
- Contact
- Rolf Soerensen
- Auditors
- Deloitte Statsautoriseret Revisionspartnerselskab
Upcoming Events for BAVA
Q1 2024 Bavarian Nordic A/S Earnings Release
Half Year 2024 Bavarian Nordic A/S Earnings Release
Q2 2024 Bavarian Nordic A/S Earnings Release
Q2 2024 Bavarian Nordic A/S Earnings Release
Similar to BAVA
Alk-Abello A/S
OMX Nordic Exchange - Copenhagen
H Lundbeck A/S
OMX Nordic Exchange - Copenhagen
H Lundbeck A/S
OMX Nordic Exchange - Copenhagen
Novo Nordisk A/S
OMX Nordic Exchange - Copenhagen
StenoCare A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 19:03 UTC, shares in Bavarian Nordic A/S are trading at DKK150.70. This share price information is delayed by 15 minutes.
Shares in Bavarian Nordic A/S last closed at DKK150.70 and the price had moved by -25.62% over the past 365 days. In terms of relative price strength the Bavarian Nordic A/S share price has underperformed the FTSE Global All Cap Index by -31.39% over the past year.
The overall consensus recommendation for Bavarian Nordic A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bavarian Nordic A/S does not currently pay a dividend.
Bavarian Nordic A/S does not currently pay a dividend.
Bavarian Nordic A/S does not currently pay a dividend.
To buy shares in Bavarian Nordic A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK150.70, shares in Bavarian Nordic A/S had a market capitalisation of DKK11.76bn.
Here are the trading details for Bavarian Nordic A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: BAVA
Based on an overall assessment of its quality, value and momentum Bavarian Nordic A/S is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bavarian Nordic A/S is DKK277.00. That is 83.81% above the last closing price of DKK150.70.
Analysts covering Bavarian Nordic A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK11.79 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bavarian Nordic A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -2.52%.
As of the last closing price of DKK150.70, shares in Bavarian Nordic A/S were trading -4.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bavarian Nordic A/S PE ratio based on its reported earnings over the past 12 months is 11.56. The shares last closed at DKK150.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bavarian Nordic A/S' management team is headed by:
- Gerard van Odijk - CHM
- Paul Chaplin - PRE
- Anders Pedersen - VCH
- Henrik Juuel - CFO
- Henrik Birk - COO
- Laurence De Moerlooze - EVP
- Jean-Christophe May - EVP
- Anu Kerns - EVP
- Anne Eberhard - IND
- Erik Hansen - IND
- Peter Kurstein-Jensen - IND
- Elizabeth McKee Anderson - IND
- Frank Verwiel - IND